Classic Congenital Adrenal Hyperplasia clinical trials

Explore recruiting classic congenital adrenal hyperplasia clinical trials.

Recruiting classic congenital adrenal hyperplasia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Classic Congenital Adrenal Hyperplasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension

Italy, Germany, France, Belgium, Netherlands, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Sweden, Netherlands, Ireland, Italy, Romania, Estonia +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia

Sweden, Austria, Poland, Netherlands, Italy, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Czechia, Portugal, Italy, Germany, Poland, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Sweden, Netherlands, Denmark, Romania, Ireland, Latvia +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Germany, France, Belgium, Spain, Poland, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Classic Congenital Adrenal Hyperplasia trials by city

Classic Congenital Adrenal Hyperplasia in Toronto Classic Congenital Adrenal Hyperplasia in Vancouver Classic Congenital Adrenal Hyperplasia in Montreal Classic Congenital Adrenal Hyperplasia in Calgary Classic Congenital Adrenal Hyperplasia in Edmonton Classic Congenital Adrenal Hyperplasia in Ottawa Classic Congenital Adrenal Hyperplasia in Winnipeg Classic Congenital Adrenal Hyperplasia in Quebec City Classic Congenital Adrenal Hyperplasia in Hamilton Classic Congenital Adrenal Hyperplasia in Kitchener Classic Congenital Adrenal Hyperplasia in London Classic Congenital Adrenal Hyperplasia in Halifax Classic Congenital Adrenal Hyperplasia in New York Classic Congenital Adrenal Hyperplasia in Los Angeles Classic Congenital Adrenal Hyperplasia in Chicago Classic Congenital Adrenal Hyperplasia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease